Serotonin: A dive of pleasure and misery

Der Pharmacia Lettre

Volumn 4, Issue 2, 2012, Pages 443-455

  Laddha, Girish P ^a   Vidyasagar, G ^b   Bavaskar, Sunil R ^c   Baile, Sunil B ^c   Suralkar, Sachin S ^c  

^a Shri Jagdish Prasad Jhabarmal Tibrewala University   (India)

^b NRVekaria Institute of Pharmacy   (India)

^c Shri Suresh dada college of Pharmacy and Research centre   (India)

Author keywords

5 hydroxytryptamine; Excitatory; Inhibitory; Neurotransmitter; Receptor; Serotonin

Indexed keywords

GANISETRON; MONOAMINE OXIDASE INHIBITOR; NOOTROPIC AGENT; ONDANSETRON; ROBALZOTAN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 5A RECEPTOR; SEROTONIN 5B RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; WAY 101405; WAY 10635;

ARTICLE; CHOLINERGIC SYSTEM; CONCENTRATION (PARAMETERS); DEPRESSION; DISEASE ASSOCIATION; DOWN REGULATION; HUMAN; LONG TERM MEMORY; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PRESYNAPTIC POTENTIAL; SEROTONIN METABOLISM; SEROTONINERGIC SYSTEM; SHORT TERM MEMORY; SIGNAL TRANSDUCTION; SYNAPSE VESICLE; TRYPTOPHAN METABOLISM; UPREGULATION;

EID: 84864307517     PISSN: None     EISSN: 09755071     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. http://www.serendip.brynmawr.edu/bb/neuro/neuro98/202s98-paper3/Frederickson3.html
2. Rawort, M. M., A. A. Green & I. H. Page.2.
3. Hamlin, K. E. & F. E. Fischek.3. Erspamek, V. 1954. Pharmacol. Revs. 6: 425.
4. Page, I. H. 1954. Physiol. Revs. 34: S63.
5. Haverback, B. J., F. A. Shore, E. G. Tomicii & H. R. Urodii,:. Twarog, B. M. & I. H. Page. An M. J. Physiol. 175: 157.
6. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP (1994). Pharmacol. Rev. 46 (2): 157-203.
7. Frazer A, Hensler JG (1999). "Chapter 13: Serotonin Receptors". In Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD, editors. Basic Neurochemistry: Molecular, Cellular, and Medical Aspects. Philadelphia: Lippincott-Raven. pp. 263-292.ISBN 0-397-51820-X. Retrieved 2008-04-11.
8. Nichols DE, Nichols CD (May 2008). Chem. Rev. 108 (5): 1614-41.
9. Francken BJ, Jurzak M, Vanhauwe JF, Luyten WH, Leysen JE. (1998). Eur J Pharmacol. 361(2-3): 299-309.
10. Glennon RA, Dukat M, Westkaemper RB (2000-01-01)."Serotonin Receptor Subtypes and Ligands". American College of Neurophyscopharmacology. Retrieved 2008-04-11.
11. "5-Hydroxytryptamine Receptors". IUPHAR Receptor Database. International Union of Basic and Clinical Pharmacology. Retrieved 2008-04-11.
12. Wesolowska A (2002). "In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors" (PDF). Polish Journal of Pharmacology 54 (4): 327-41
13. Tomkins DM, Higgins GA, Sellers EM (1994). Psychopharmacology (Berl). 115(1-2): 173-9.
14. Müller CP, Carey RJ, Huston JP, De Souza Silva MA (2007). Prog Neurobiol. 81 (3): 133.
15. Carey RJ, DePalma G, Damianopoulos E, Shanahan A, Müller CP, Huston JP (2005). Brain Res. 1034 (1-2): 162-71
16. de Boer SF, Koolhaas JM (2005). Eur J Pharmacol. 526 (1-3): 125-39
17. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M (1998). Proc Natl Acad Sci U S A. 195 (18): 10734-9.
18. Ebenezer IS, Arkle MJ, Tite RM (1998). Methods Find Exp Clin Pharmacol. 29 (4): 269-72.
19. Wouters W, Tulp MT, Bevan P (1998). Eur J Pharmacol. 149 (3): 213-23.
20. Horiuchi J, McDowall LM, Dampney RA (2008). Auton Neurosci. 142 (1-2): 71-6.
21. Nalivaiko E, Ootsuka Y, Blessing WW. (2005). Am J Physiol Regul Integr Comp Physiol. 289(2): R596-R604.
22. Lucot JB. (1994). Eur J Pharmacol. 253 (1-2): 53-60.
23. Winstanley CA, Theobald DE, Dalley JW, Robbins TW. (2005). Neuropsychopharmacology. 30 (4): 669-682
24. Ogren SO, Eriksson TM, Elvander-Tottie E, D'Addario C, Ekström JC, Svenningsson P, Meister B, Kehr J, Stiedl O (2008). Behav Brain Res.195 (1): 54-77
25. Yasuno F, Suhara T, Nakayama T, Ichimiya T, Okubo Y, Takano A, Ando T, Inoue M, Maeda J, Suzuki K (2003). Am J Psychiatry 160 (2): 334-40.
26. Kennett GA, Dourish CT, Curzon G (1987). Eur J Pharmacol. 134 (3): 265-74.
27. Bardin L, Tarayre JP, Malfetes N, Koek W, Colpaert FC. (2003). Pharmacology. 67 (4): 182-194
28. Millan MJ, Perrin-Monneyron S (1997). Eur J Pharmacol. 321 (3): 11-3.
29. Prow MR, Martin KF, Heal DJ (1996). Eur J Pharmacol. 317 (1): 21-8.
30. Meyer LC, Fuller A, Mitchell D (February 2006). American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 290 (2): R405-13.
31. Popova NK, Amstislavskaya TG (2002). Psychoneuroendocrinology 27 (5): 609-18.
32. Monti JM, Jantos H (1992). J Sleep Res. 1 (3): 169-175
33. Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (2007). Neuroscience 146 (2): 509-14
34. Gudelsky GA, Koenig JI, Meltzer HY (1986). Neuropharmacology 25 (12): 1307-13.
35. Ootsuka Y, Blessing WW. (2006). Brain Res. 1073-1074: 252-61. pharmamotion.com Serotonin (5-HT): receptors, agonists and antagonists By Flavio Guzman, M.D. on 9/08/09
36. Harrison AA, Parsons LH, Koob GF, Markou A (1999). Psychopharmacology (Berl). 141 (3): 242-50.
37. Chojnacka-Wójcik E, Klodzinska A, Tatarczynska E (2005). J Pharm Pharmacol. 57 (2): 253-7.
38. Lin D, Parsons LH (2002). Pharmacol Biochem Behav. 71 (4): 581-7..
39. Tatarczynska E, Klodzinska A, Stachowicz K, Chojnacka-Wójcik E (2004). Behav Pharmacol. 15 (8): 523-34.
40. Eriksson TM, Madjid N, Elvander-Tottie E, Stiedl O, Svenningsson P, Ogren SO (2008). Neuropharmacology 54 (7): 1041-50.
41. McCreary AC, Bankson MG, Cunningham KA (1999). J Pharmacol Exp Ther. 290 (3): 965-73.
42. Amital D, Fostick L, Sasson Y, Kindler S, Amital H, Zohar J (2005). Eur Neuropsychopharmacol. 15 (3): 279-82.
43. Feuerstein TJ, Huring H, van Velthoven V, Lucking CH, Landwehrmeyer GB. (1996). Neurosci Lett. 209 (3): 210-4.